Cognitive-behavioral therapy in high-altitude respiratory care: Critical considerations for physiological interpretation

Abstract

High-altitude respiratory diseases, characterized by hypoxia-induced complications such as pulmonary edema and chronic bronchitis, present critical challenges to both physical and mental health in vulnerable populations. The recent study by Meng et al demonstrates that integrating cognitive-behavioral therapy (CBT) with standard care significantly improves anxiety levels and sleep quality in affected patients. These key findings hold direct implications for advancing respiratory management in hypoxic environments. Meng et al’s observation of reduced serum hypoxia biomarkers (hypoxia-inducible factor-1α and erythropoietin) further suggests potential enhancements in physiological adaptation. However, the interpretation of these biomarker changes as evidence of improved hypoxia tolerance requires cautious examination. The study’s reliance on indirect indicators fails to establish whether CBT’s benefits stem primarily from psychological modulation or genuine cellular adaptation. Furthermore, the 5-day intervention window coincides with the half-life of erythropoietin, raising questions about the durability of these effects in the context of hypoxic acclimatization, which typically requires weeks to months. To resolve these ambiguities, future studies should prioritize longitudinal designs tracking both respiratory function and molecular biomarkers over clinically relevant timeframes. Integrating CBT with objective pulmonary assessments would clarify its role in optimizing oxygen utilization pathways. Such advances could refine targeted interventions for high-altitude respiratory rehabilitation, ultimately strengthening evidence-based care for this unique patient population.

Key Words: Cognitive-behavioral therapy; High-altitude respiratory diseases; Hypoxia biomarkers; Physiological adaptation; Rehabilitation

Core Tip: Cognitive-behavioral therapy significantly alleviates anxiety and improves sleep quality in high-altitude respiratory patients. However, rapid reductions in hypoxia biomarkers (hypoxia-inducible factor-1α and erythropoietin) after 5-day interventions more likely reflect transient stress modulation than durable physiological adaptation, given their discordance with natural acclimatization timelines. Future studies should prioritize longitudinal biomarker tracking, objective physiological measures (e.g., tissue oxygenation), and medication-stratified analyses to definitively establish the role of cognitive-behavioral therapy in hypoxia tolerance—a distinction vital for optimizing high-altitude rehabilitation.

TO THE EDITOR

We read with considerable interest the rigorous study by Meng et al[1]. Their study demonstrated that a 5-day adjunctive cognitive-behavioral therapy (CBT) protocol significantly improved anxiety symptoms and sleep quality, while concurrently reducing serum levels of hypoxia-related biomarkers in 2337 patients with high-altitude respiratory diseases. While we commend the authors for addressing the critical mind-body interface in hypoxic environments, several interpretive dimensions concerning biomarker dynamics merit scholarly discussion to refine clinical translation.

STUDY OVERVIEW AND DISCUSSION

The trial’s integrated psychological–respiratory approach yielded compelling outcomes. Notably, the CBT group achieved significantly lower post-intervention Hamilton Anxiety Scale scores (6.97 ± 1.12 vs 7.74 ± 1.09, P < 0.05), a finding consistent with meta-analytic evidence on respiratory therapies for anxiety in similar patient populations[2]. Significant reductions in Pittsburgh Sleep Quality Index scores (5.17 ± 1.08 vs 7.43 ± 1.35) and improved sleep efficiency (72.18% ± 8.12% vs 60.23% ± 9.26%) were also observed. Most notably, serum levels of hypoxia-inducible factor-1α (HIF-1α) and erythropoietin (EPO) decreased significantly in the CBT group (32.19 ± 3.24 ng/mL and 33.27 ± 2.23 mIU/mL, respectively) compared to controls (37.24 ± 3.15 ng/mL and 39.31 ± 2.34 mIU/mL).

The authors suggest these biomarker shifts indicate enhanced hypoxia tolerance through psychological modulation. However, equating reduced biomarker levels with improved physiological adaptation warrants caution. The physiology of EPO presents a critical temporal paradox: Given its serum half-life of 5-9 hours[3], the reported 50% reduction in EPO (from 67.25 ± 8.14 mIU/mL to 33.27 ± 2.23 mIU/mL) precisely mirrors expected metabolic clearance within the 5-day intervention period. This observation raises questions about whether the change represents a transient stress-response modulation rather than durable acclimatization. The interpretation aligns with established pathophysiology. Comprehensive reviews confirm that durable hypoxic adaptation requires weeks to months for vascular remodeling, erythropoiesis, and metabolic adjustments[3,4]—fundamentally incompatible with a 5-day intervention. Shifting focus to HIF-1α dynamics, these may be confounded by standard medical interventions. Anti-inflammatory agents (e.g., corticosteroids), administered according to the study’s symptomatic treatment protocol, can suppress HIF-1α via nuclear factor kappaB pathway inhibition, potentially obscuring CBT-specific effects. Critically, deficiency of IkappaB kinase-beta or nuclear factor kappa B in vivo leads to defective induction of HIF-1α target genes (e.g., vascular endothelial growth factor) and exacerbates tissue damage under hypoxia[5], demonstrating this pathway’s physiological necessity for adaptation.

STRENGTHS AND CLINICAL RELEVANCE

This trial offers substantial methodological strengths, including an exceptionally large sample size (n = 2337), which is rarely achieved in high-altitude medicine; validated psychometric instruments; and clinically significant effect sizes. The CBT group demonstrated a high level of health knowledge mastery (93.64%) and high intervention satisfaction (95.53%), underscoring its value in enhancing patient engagement—a crucial factor in chronic respiratory management. The correlation between psychological improvement and biomarker changes aligns with emerging evidence that CBT modulates autonomic nervous system function. This modulation may reduce anxiety-driven hyperventilation and improve oxygen utilization efficiency. Chronic sleep disturbance, associated with anxiety disorders, increases sympathetic outflow and inflammatory responses; in contrast, behavioral interventions may restore autonomic balance[6]. These findings position CBT as a scalable, low-risk adjunct to standard care, particularly for anxiety-exacerbated respiratory distress in resource-constrained high-altitude settings. The observed extension in sleep duration (371.15 ± 31.23 min vs 329.26 ± 33.34 min) may confer critical recovery benefits, as fragmented sleep exacerbates hypoxemia by increasing metabolic demand. This mechanism is biologically plausible: Experimental sleep fragmentation significantly elevates nocturnal metabolic rate (CO₂ uptake and O₂ uptake) relative to baseline sleep conditions, even after controlling for reduced total sleep time. These findings demonstrate how elevated metabolic demand undermines sleep’s restorative function[7], thereby strengthening our clinical hypothesis.

STUDY LIMITATIONS

While the study advances high-altitude care paradigms, three limitations merit consideration.

First, the temporal misalignment between the 5-day intervention and naturalistic hypoxic adaptation processes is physiologically consequential. Erythropoietic responses to EPO require 3-5 days for reticulocyte emergence and weeks for hemoglobin elevation. Without longitudinal tracking, the durability of biomarker changes remains unsubstantiated. It remains unresolved whether CBT induces transient stress buffering or sustained acclimatization. This interpretation aligns with fundamental pathophysiology. Comprehensive reviews indicate that complete hypoxic adaptation requires weeks to months for vascular remodeling, erythropoiesis, and metabolic adjustments. These processes are fundamentally incompatible with the 5-day intervention window[8]. This temporal limitation finds parallels in other clinical contexts; for instance, digital CBT interventions typically require 12-week protocols to demonstrate sustained improvements, as shown in Heinrich et al’s randomized controlled trial in patients with breast cancer[9], aligning with known timelines for meaningful adaptations. Similarly, preoperative CBT in bariatric surgery failed to show durable physiological benefits at the 3-5-year follow-up despite initial psychological gains, with both groups exhibiting weight regain and worsening depressive symptoms[10]. Furthermore, the effectiveness of CBT depends on adequate clinical supervision to enhance therapist competence and outcomes. As therapist experience significantly predicts therapeutic success, and our 5-day protocol inherently limits such experiential factors, claims about physiological adaptation require caution[11].

Second, group heterogeneity introduces interpretive ambiguity. The control group consisted of 1912 individuals (74.23% of the cohort) with prior high-altitude experience, while the intervention group comprised exclusively high-altitude novices (Group A: 425 first-time entrants). This imbalance risks confounding, as pre-existing physiological adaptations in controls could attenuate biomarker responsiveness relative to the CBT group’s naïve hypoxia response. Thirdly, the physiological specificity of biomarker reductions warrants clarification. While lower HIF-1α and EPO levels suggest reduced hypoxic stress, this does not intrinsically equate to improved physiological tolerance. Direct measures of tissue oxygenation, such as muscle or cerebral oxygenation assessed by near-infrared spectroscopy[12], or exercise capacity under controlled hypoxia would strengthen causal inference. Recent machine learning models for high-altitude pulmonary edema severity stratification reinforce this caution[13]. These algorithms prioritize direct, real-time physiological indicators, including oxygen saturation (SpO₂) and auscultatory findings, over serum biomarkers owing to the superior reliability of physiological indicators in reflecting acute hypoxic stress.

FUTURE DIRECTIONS

Given that erythropoietic adaptation requires ≥ 4 weeks to produce measurable changes in hemoglobin mass, future trials should implement CBT protocols lasting 4-8 weeks, with weekly biomarker assessments and monthly follow-up of respiratory function to distinguish transient effects from genuine physiological adaptation. In addition, medication-stratified analyses should be conducted to isolate the specific effects of CBT from the pharmacological modulation of HIF-1α inherent to standard respiratory treatments. These studies would be further strengthened by integrating hypoxic challenge protocols that quantify oxygen saturation stability during standardized exercise, thereby providing objective evaluations of physiological resilience. Moreover, rigorous cohort stratification based on altitude exposure history is essential to control for pre-existing adaptive advantages in hypoxia tolerance. This should be complemented by economic evaluations comparing the long-term cost-effectiveness of CBT against pharmacological alternatives for managing anxiety-related hyperventilation in high-altitude populations.

CONCLUSION

Meng et al[1] provide compelling evidence for the psychological benefits of CBT in high-altitude respiratory care. However, interpreting the rapid reduction of HIF-1α and EPO as indicative of enhanced hypoxia tolerance requires careful contextualization. Longer-term studies integrating direct physiological measurements are needed to clarify whether CBT enhances hypoxic adaptation, a process requiring weeks to months. To validate the role of CBT in hypoxia tolerance, we advocate for integrated protocols that pair CBT interventions lasting ≥ 4 weeks with objective hypoxic stress testing (e.g., oxygen saturation stability during standardized exercise), providing clinically actionable metrics for individualized rehabilitation. Such refinements will accelerate the development of evidence-based rehabilitation strategies for this vulnerable population.